• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [16962 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2008     NIHR Health Technology Assessment programme 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis
1999     NIHR Health Technology Assessment programme 'Early warning systems' for identifying new healthcare technologies
2001     Danish Institute for Health Services Research (DSI) 'Health projekc Ebeltoft'. General practitioners valuation of organisational aspects by implementing preventive examination of health and conversation in general practitioner. DSI Rapport 2001.05
2002     Centre for Clinical Effectiveness (CCE) 'Open' versus 'closed' systems for enteral feeding
2000     Alberta Heritage Foundation for Medical Research (AHFMR) 'Soft copy' digital mammography
2003     NIHR Health Technology Assessment programme "CLIP" Central Line Insertion Project, primary research
2005     Israel Center for Technology Assessment in Health Care (ICTAHC) "Publication profile" of an innovative technology - case study: coronary stent (abstract)
2005     Israel Center for Technology Assessment in Health Care (ICTAHC) "Techno-markers" for health technology utilization assessment (abstract)
2000     ECRI (111)In-capromab pendetide for staging prostate cancer in men at high risk of metastasis
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) (Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation. 3rd Update 2018
2008     Committee for New Health Technology Assessment (CNHTA) [1) PCCA gene, mutation[sequencing] 2) PCCB gene, mutation[sequencing]]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [10th Symposium Health Technology Assessment, Nothing without evidence? 18th-19th March 2010, Cologne]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [11th Symposium Health Technology Assessment, theoretical practice - practical theory? 17th to 18th March 2011, Cologne]
2010     Committee for New Health Technology Assessment (CNHTA) [18-f-sodium fluoride (18-f-naf) bone positron emission tomography, positron emission tomography/computed tomography]
2004     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [18-FDG positron emission tomography in oncology: HTA reports by international HTA agencies]
2012     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [1st Expert Panel on viper venomous bite in Spain]
2007     Andalusian Health Technology Assessment Area (AETSA) [3 Tesla Magnetic Resonance Imaging]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [3D Echocardiography in heart valve diseases]
2010     Andalusian Health Technology Assessment Area (AETSA) [4D Ultrasound]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [8th Symposium Health Technology Assessment - Decision-making in medicine, 2007, October 18 - 19, Cologne]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [9th Symposium Health Technology Assessment - Patients in no man's land, 2008, October 17 - 18, Cologne]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [A construction of support scheme for health technology evidence-generation in Korea]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A health technology assessment of the effectiveness and safety of robot surgery]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [A health technology evaluation study for reviewing possibility of data linkage]
2011     Haute Autorite de sante (HAS) [A priori evaluation of the expansion of newborn screening to one or more inborn error(s) of metabolism using the technology of tandem mass spectrometry in the general population in France. Part 1: medium chain CoA dehydrogenase deficiency (MCADD)]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A research on evidence-based healthcare for thyroid cancer screening. Part 1 : the current status of thyroid cancer screening]
2013     Andalusian Health Technology Assessment Area (AETSA) [A review of indications for ventricular assist device therapy]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study of high-risk dyslipidemia for cardiocerebrovascular disease in Koreans]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [A study of the effectiveness of self-care interventions for subclinical and mild depression]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on current issues of hearing aid use in Korean patients with hearing loss]
2010     Andalusian Health Technology Assessment Area (AETSA) [A study on efficacy, effectivity and efficiency of Intensity Modulated Radiotherapy (IMRT). Utility for treatment of breast and central nervous system neoplasms and sarcomas of bones and soft tissue]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on Korean adolescents' risk factors of suicide]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the evaluation standards of osteoporosis in Korea]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the factors influencing adherence to antidepressant therapies and the cost-effectiveness of antidepressant therapies in Korea]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the system and execution model for health technology reassessment]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A systematic review of the diagnostic accuracy of FDG PET/PET-CT for fever of unknown origin]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [A16-05 dabrafenib/trametinib - addendum to commissions A15-39 and A15-40]
2009     Committee for New Health Technology Assessment (CNHTA) [AB0-Rh(D) blood grouping automation test using CAT (column agglutination technology)]
2007     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Abatacept in the treatment of rheumatoid arthritis; systematic review and economic evaluation]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (New therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2008     Committee for New Health Technology Assessment (CNHTA) [Access flow measurement for hemodialysis]
2009     Committee for New Health Technology Assessment (CNHTA) [Acellular dermal graft]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium bromide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium bromide - benefit assessment according to §35a Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium/formoterol: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013     Andalusian Health Technology Assessment Area (AETSA) [Active immunotherapy for breast cancer]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Active knee motion devices in the treatment of anterior cruciate ligament ruptures]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Active mobilization after flexor tendon repairs in zone II of the hand]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Active mobilization after flexor tendon repairs in zone II of the hand]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Actualization: radiofrequency sympathetic denervation of the renal arteries for refractory arterial hypertension]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Acupuncture - areas of application, current evidence and proven indications]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for carpal tunnel syndrome]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for headache]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for lateral epicondylitis]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for treating lumbago]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Acute neck and back pain: preventive interventions – effects of physical training, manual treatment and cognitive behavioral interventions]
2013     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Acute pain treatment on postoperative and medical non-surgical wards]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Adalimumab for treating rheumatoid arthritis]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis]
2009     Committee for New Health Technology Assessment (CNHTA) [ADAMTS 13 Activity]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Adaptation to the Catalan health care system of the clinical practice guideline 'Management of major depression in adults']
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-15 Crizotinib]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-16 Saxagliptin/metformin]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-03 (sitagliptin/metformin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-05 (fidaxomicin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-06 (abiraterone acetate [new therapeutic indication])]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-09 (vandetanib)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-10 (pertuzumab)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-16 (vildagliptin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-17 (vildagliptin/metformin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-33 (enzalutamide)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-35 (dabrafenib)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-37 (regorafenib)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-44 (ipilimumab)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A14-05 (sofosbuvir)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-12 (canagliflozin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A14-14 (dimethyl fumarate)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-18 (simeprevir)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-19 (mirabegron)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-21 (fingolimod)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-26 (empagliflozin)]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to the final report A09-02 (benefit assessment of prasugrel)]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2008     Committee for New Health Technology Assessment (CNHTA) [Adenovirus, nested PCR]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [Advantages of vestibular rehabilitation on the vestibular neuritis]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Advisability of expanding the Québec newborn blood screening program]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afamelanotide - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Addendum to Commission A14-32)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (extension of approval) - benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Eylea) extension of approval: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) – benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Zaltrap) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Aflibercept for age-related macular degeneration and central retinal vein occlusion]